Clinical review report: Tocilizumab (Actemra) (Hoffmann-La Roche Limited)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, April 2018
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of tocilizumab 162 mg/0.9 mL pre-filled syringe for subcutaneous (SC) injection for the treatment of giant cell arteritis (GCA) in adults |
---|---|
Item Description: | "Version: final." |
Physical Description: | 1 PDF file (63 pages) illustrations |